Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-07-05
DOI
10.3389/fphar.2022.880090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis
- (2021) Conor Hanrahan et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
- (2021) Dmytro Trukhin et al. BIODRUGS
- Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
- (2021) Konstantinos Syrigos et al. BIODRUGS
- Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
- (2021) Shukui Qin et al. BIODRUGS
- Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies
- (2021) Aqsa Safdar et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
- (2021) Yuankai Shi et al. Cancer Communications
- Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
- (2020) Yunpeng Yang et al. Translational Lung Cancer Research
- Efficacy and safety of proposed bevacizumab biosimilar BE1040V in patients with metastatic colorectal cancer: A phase III, randomized, double-blind, noninferiority clinical trial
- (2020) Hamid Rezvani et al. CLINICAL THERAPEUTICS
- A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer
- (2020) Martin Reck et al. LUNG CANCER
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Cancer statistics for adolescents and young adults, 2020
- (2020) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials
- (2020) Sarah Cargnin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- How do biosimilars sustain value, affordability, and access to oncology care?
- (2020) Steven Simoens Expert Review of Pharmacoeconomics & Outcomes Research
- Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study
- (2019) Nicholas Thatcher et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2019) Jichun Yang et al. BIODRUGS
- PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
- (2019) Niels Reinmuth et al. BIODRUGS
- Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients
- (2018) Edoardo Botteri et al. EUROPEAN JOURNAL OF CANCER
- Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
- (2018) Romina Brignardello-Petersen et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Biosimilars: Review of current applications, obstacles, and their future in medicine
- (2018) Flyn Kaida-Yip et al. World Journal of Clinical Cases
- GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence
- (2018) Romina Brignardello-Petersen et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- A Bayesian network meta-analysis for binary outcome: how to do it
- (2016) Teresa Greco et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer
- (2015) Lindsey E. Minion et al. GYNECOLOGIC ONCOLOGY
- Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases
- (2015) Alexander Nast et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries
- (2014) Ivo Abraham et al. Future Oncology
- A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
- (2014) M. A. Puhan et al. BMJ-British Medical Journal
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- A basic introduction to fixed-effect and random-effects models for meta-analysis
- (2010) Michael Borenstein et al. Research Synthesis Methods
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started